| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm |
| Cash burn (monthly) | 2.87 mm | 2.84 mm | 2.45 mm | 3.51 mm | 2.87 mm | 3.63 mm |
| Cash used (since last report) | 68.18 mm | 67.59 mm | 58.24 mm | 83.39 mm | 68.17 mm | 86.44 mm |
| Cash remaining | -42.48 mm | -41.89 mm | -32.54 mm | -57.69 mm | -42.47 mm | -60.74 mm |
| Runway (months of cash) | -14.8 | -14.7 | -13.3 | -16.5 | -14.8 | -16.7 |
| 13F holders | Current |
|---|---|
| Total holders | 4 |
| Opened positions | 0 |
| Closed positions | 20 |
| Increased positions | 0 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 33.78 mm |
| Total shares | 15.51 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | 14.82 mm | $29.78 mm |
| Biotechnology Value Fund L P | 488.37 k | $0.00 |
| Primecap Management | 199.96 k | $82.00 k |
| FinTrust Capital Advisors | 1.20 k | $3.92 mm |
| INCY Incyte | 0.00 | $0.00 |
